enGene Holdings Inc. Files 8-K Report
Ticker: ENGNW · Form: 8-K · Filed: Sep 30, 2025 · CIK: 1980845
Sentiment: neutral
Topics: corporate-filing, 8-K
TL;DR
enGene Holdings Inc. filed an 8-K, confirming their HQ address in Saint-Laurent, Quebec.
AI Summary
On September 30, 2025, enGene Holdings Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada. The report does not disclose specific financial transactions or material events beyond the company's basic corporate information.
Why It Matters
This 8-K filing confirms the registered address and basic corporate information for enGene Holdings Inc., providing an update for investors regarding the company's official location.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information that suggests immediate financial risk or opportunity.
Key Players & Entities
- enGene Holdings Inc. (company) — Registrant
- September 30, 2025 (date) — Date of earliest event reported
- 4868 Rue Levy, Suite 220 (address) — Principal Executive Offices
- Saint-Laurent, Quebec, Canada (location) — City, Province, Country of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for enGene Holdings Inc.?
The primary purpose of this 8-K filing is to report current information as required by the SEC, specifically detailing the company's principal executive offices and confirming its corporate structure as of September 30, 2025.
Where are enGene Holdings Inc.'s principal executive offices located?
enGene Holdings Inc.'s principal executive offices are located at 4868 Rue Levy, Suite 220, Saint-Laurent, Quebec, Canada.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is September 30, 2025.
What is the Commission File Number for enGene Holdings Inc.?
The Commission File Number for enGene Holdings Inc. is 001-41854.
Under which section of the Securities Exchange Act is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-30 07:36:10
Key Financial Figures
- $11.50 — e Common Share, at an exercise price of $11.50 per Share ENGNW The Nasdaq Stock Ma
Filing Documents
- engn-20250930.htm (8-K) — 52KB
- engn-ex99_1.htm (EX-99.1) — 25KB
- img7790613_0.jpg (GRAPHIC) — 115KB
- 0001193125-25-224053.txt ( ) — 382KB
- engn-20250930.xsd (EX-101.SCH) — 46KB
- engn-20250930_htm.xml (XML) — 7KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 30, 2025, the Company issued a press release announcing the appointment of Dr. Hussein Sweiti as Chief Medical Officer, a copy of which is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of the Company dated September 30, 2025. 104 Cover Page Interactive Data File (Formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENGENE HOLDINGS INC. Date: September 30, 2025 By: /s/ Ronald H.W. Cooper Name: Ronald H.W. Cooper Title: Chief Executive Officer and President